论文部分内容阅读
目的分析支原体感染盆腔炎行阿奇霉素联合盆腔炎2号方治疗的效果。方法 95例支原体感染盆腔炎患者,随机分为观察组(50例)和对照组(45例)。观察组采用阿奇霉素联合盆腔炎2号方治疗,对照组采用头孢西丁联合盆腔炎2号方治疗,比较两组治疗效果与不良反应发生情况。结果治疗后观察组的子宫血流动力指标均优于对照组,差异具有统计学意义(P<0.05)。观察组总不良反应发生率为10.00%,低于对照组的26.67%(χ~2=4.478,P<0.05)。结论治疗支原体感染盆腔炎采用阿奇霉素联合盆腔炎2号方治疗能有效的提高临床治疗疗效,不良反应发生较少,值得临床推广应用。
Objective To analyze the effect of mycoplasma infection combined with pelvic inflammatory disease azithromycin combined pelvic inflammatory disease on the 2nd. Methods 95 patients with mycoplasma infection of pelvic inflammatory disease, were randomly divided into observation group (50 cases) and control group (45 cases). The observation group was treated with azithromycin combined with pelvic inflammatory disease on the 2nd, and the control group was treated with cefoxitin combined with pelvic inflammatory disease on the 2nd, the treatment effect and adverse reactions were compared between the two groups. Results After treatment, the uterine hemodynamic indexes in the observation group were better than those in the control group, with statistical significance (P <0.05). The incidence of adverse reactions in the observation group was 10.00%, which was lower than 26.67% in the control group (χ ~ 2 = 4.478, P <0.05). Conclusion The treatment of mycoplasma infection with pelvic inflammatory disease azithromycin combined with pelvic inflammatory disease on the 2nd treatment can effectively improve the efficacy of clinical treatment, adverse reactions occur less worthy of clinical application.